GSK announces depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 17:00 Hrs [IS ...

GSK (GSK) announced that new drug applications have been accepted for review by the China National Medical Products Administration and ...

GSK plc (LSE/NYSE: GSK) today announced that new drug applications have been accepted for review by the China National Medical Products Administration and submitted to the Japanese Ministry of Health, ...

What is bronchitis? “Bronchitis is a respiratory condition characterised by inflammation of the airways in the lungs,” says ...

If you've been dealing with a persistent nasty cough, you may be wondering whether it's just a seasonal cold or something ...

A simple, noninvasive nasal swab identified a predominance of T2-low asthma subtypes in racial and ethnic minority pediatric ...

Between the 2017-2018 and 2023-2024 influenza seasons, the use of antiviral therapy in pediatric patients with influenza declined in both inpatient and outpatient settings.

Those with asthma should try to stay indoors during extreme cold, especially when temperatures dip below 10 degrees ...

or other nonsteroidal anti-inflammatory medications (NSAIDs) if you are taking any other blood thinners or have any of these conditions — bleeding problems, asthma, recent or upcoming surgery ...

Juan Celedón and his research team have altered the possibilities of future asthma treatment by uncovering a new way to ...

Specifically, Dupixent is approved to treat moderate to severe asthma that is either: dependent on treatment with an oral corticosteroid, or eosinophilic (caused by an increase in eosinophils ...